KRW 96700.0
(-6.84%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 528.37 Million KRW | 144.16% |
2022 | 216.4 Million KRW | -97.63% |
2021 | 9.14 Billion KRW | 153.24% |
2020 | 3.61 Billion KRW | 90.11% |
2019 | 1.9 Billion KRW | 0.0% |
2018 | - KRW | -100.0% |
2017 | 8.51 Billion KRW | 8.48% |
2016 | 7.85 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | - KRW | 0.0% |
2024 Q1 | 128.67 Million KRW | 0.0% |
2023 Q1 | 174.6 Million KRW | 0.0% |
2023 Q4 | 528.37 Million KRW | 229.47% |
2023 Q3 | 160.36 Million KRW | 5.93% |
2023 Q2 | 151.38 Million KRW | -13.3% |
2023 FY | 528.37 Million KRW | 144.16% |
2022 Q3 | 9.14 Billion KRW | 0.0% |
2022 Q4 | - KRW | -100.0% |
2022 Q2 | 9.14 Billion KRW | 0.0% |
2022 Q1 | 9.14 Billion KRW | 0.0% |
2021 Q3 | 11.84 Billion KRW | 0.0% |
2021 Q4 | 9.14 Billion KRW | -22.79% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
HLB Co., Ltd. | 17.93 Billion KRW | 97.054% |
iNtRON Biotechnology, Inc. | 258.29 Million KRW | -104.562% |
BINEX Co., Ltd. | 5.57 Billion KRW | 90.528% |
Bioneer Corporation | 12.5 Billion KRW | 95.773% |
Anterogen.Co.,Ltd. | - KRW | -Infinity% |
MEDIPOST Co., Ltd. | 6.99 Billion KRW | 92.446% |
CrystalGenomics, Inc. | 29.88 Billion USD | 98.232% |
Helixmith Co., Ltd | 151.68 Million KRW | -248.347% |
Chabiotech Co.,Ltd. | 95.06 Billion KRW | 99.444% |
Medy-Tox Inc. | 1.22 Billion KRW | 56.897% |
Peptron, Inc. | 4.5 Billion KRW | 88.258% |
Amicogen, Inc. | 70.65 Billion KRW | 99.252% |
Genexine, Inc. | 22.68 Billion KRW | 97.67% |
HLB Therapeutics Co.,Ltd. | 1.84 Billion KRW | 71.287% |
ALTEOGEN Inc. | 1.24 Billion KRW | 57.705% |
PharmaResearch Co., Ltd. | 970.71 Million KRW | 45.569% |
SillaJen, Inc. | 8.13 Billion KRW | 93.506% |
JETEMA, Co., Ltd. | 60 Billion KRW | 99.119% |
OliX Pharmaceuticals,Inc | 35.36 Billion KRW | 98.506% |
Genomictree Inc. | 97.51 Million KRW | -441.834% |
MedPacto, Inc. | 1.68 Billion KRW | 68.679% |
D&D Pharmatech | 5.12 Billion KRW | 89.681% |
EASY BIO,Inc. | 30 Billion KRW | 98.239% |
GI Innovation, Inc. | 2.9 Billion KRW | 81.805% |